Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...
Drug
3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint
China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...
Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...
3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing
China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has...
Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...
Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing...
Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...
Zhaoke Ophthalmology Enrolls First Patients for ZKY001 in Phase II Trials
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...
MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in...
Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan
China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study...
Cyramza Prescribed in China for Advanced Gastric Cancer
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...
Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD
China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a...
Ji Xing Pharmaceuticals’ Omecamtiv Mecarbil Accepted for Review by CDE
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that a market filing for its...
Innovent Biologics’ Tafolecimab Shows Strong LDL-C Reduction in Phase III Study
China-based Innovent Biologics, Inc. (HKG: 1801) announced the results of the Phase III CREDIT-1 study...
Ascentage Pharma Presents APG-1387 Phase I Study Results at AASLD
Hong Kong-based biotech Ascentage Pharma (HKG: 6855) presented the Phase I clinical study results of...
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...